Breaking News Instant updates and real-time market news.

ABBV

AbbVie

$76.84

-0.62 (-0.80%)

08:37
05/14/19
05/14
08:37
05/14/19
08:37

AbbVie resolves HUMIRA U.S. patent litigation with Boehringer Ingelheim

AbbVie announced that it has resolved U.S. HUMIRA litigation with Boehringer Ingelheim. Under the terms of the resolution, AbbVie will grant BI a non-exclusive license to its HUMIRA-related intellectual property in the United States. The U.S. license for BI will begin on July 1, 2023. BI will pay royalties to AbbVie for licensing its HUMIRA patents and acknowledges the validity and enforceability of the licensed patents. AbbVie will make no payments of any form to BI. "This is an important settlement as it resolves all HUMIRA-related patent litigation in the U.S and provides access for another biosimilar manufacturer seeking to enter the U.S.," said Laura Schumacher, Vice Chairman, External Affairs and Chief Legal Officer at AbbVie. "As an innovation-driven biopharmaceutical company, we will continue to develop novel cures for the toughest health challenges and rely on a robust patent system to protect that investment in innovation."

  • 18

    May

  • 31

    May

  • 05

    Jun

ABBV AbbVie
$76.84

-0.62 (-0.80%)

03/25/19
03/25/19
DOWNGRADE

Hold
AbbVie downgraded to Hold from Buy at Argus
As previously reported, Argus analyst David Toung downgraded AbbVie to Hold, saying its flagship program Humira "no longer looks invulnerable to competition from biosimilars in Europe and other overseas markets." The analyst notes that Humira is also faced with "indirect competition from newer drugs that have an alternative mechanism of action" compared to Humira's anti-TNF class. Toung further cites AbbVie's clinical setback with Venclexta, which highlights the risks for the company as it develops a pipeline aimed to offset the expected decline in Humira sales.
03/26/19
WBLR
03/26/19
UPGRADE
WBLR
Outperform
William Blair upgrades Vertex to Outperform after 'subpar' competitor data
William Blair analyst Y. Katherine Xu upgraded Vertex Pharmaceuticals (VRTX) to Outperform from Market Perform on expectations the company's cystic fibrosis franchise will continue dominating after Proteostasis (PTI) reported disappointing triplet data. Proteostasis' triplet efficacy falls short of the high bar set by the Vertex triples, Xu tells investors in a research note. While Proteostasis is starting a Phase II study of the triplet that would include a higher PTI-808 dose and test a longer duration aiming to optimize response with data out around year-end 2019, the chance of it matching or exceeding Vertex triple efficacy is "very low," contends the analyst. With both Galapagos (GLPG)/AbbVie (ABB) and Proteostasis having shown "subpar data," Xu is upgrading Vertex shares to Outperform and raised her fair value estimate for the shares to $222 from $178. The analyst maintains her high probability of success of a Vertex triple combo reaching the cystic fibrosis market at 90% and ascribe peak sales of $10.2B, up from $8.9 billion previously.
04/11/19
EVER
04/11/19
INITIATION
Target $30
EVER
Outperform
Myovant Sciences initiated with an Outperform at Evercore ISI
Evercore ISI analyst Ravi Mehrotra initiated Myovant Sciences (MYOV) with an Outperform rating and a price targets of $30. The analyst says the company's lead program relugolix has been clinically de-risked with near-term pivotal data readouts. Mehrotra is modeling revenues of $944M for the program by 2023 thanks to its "commercial advantage of a one-a-day pill" and the "second-mover leverage of competitor AbbVie's (ABBV) efforts to raise awareness and diagnosis" in woman's health market.
04/28/19
BMOC
04/28/19
UPGRADE
Target $79
BMOC
Market Perform
AbbVie upgraded to Market Perform from Underperform at BMO Capital
BMO Capital analyst Alex Arfaei upgraded AbbVie to Market Perform from Underperform and raised his price target for the shares to $79 from $71. The stock closed Friday up 29c to $79.70. The analyst says his bearish thesis has mostly materialized and that he's now more bullish on Skyrizi and Upa. AbbVie can leverage its rebates to secure superior access in the U.S. and drive "strong" launches, Arfaei tells investors in a research note. He believes after a flat 2019, Skyrizi, Upa, Imbruvica/Venclexta and Orilissa should drive 4%-6% revenue growth during 2020-2022. This should improve sentiment on shares of AbbVie, says the analyst.

TODAY'S FREE FLY STORIES

GSK

GlaxoSmithKline

$39.97

-0.22 (-0.55%)

10:45
05/23/19
05/23
10:45
05/23/19
10:45
Hot Stocks
GSK to change sales representative incentive program »

The company said,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

10:45
05/23/19
05/23
10:45
05/23/19
10:45
General news
he April U.S. new home sales report beat estimates »

The April U.S. new home…

10:45
05/23/19
05/23
10:45
05/23/19
10:45
General news
Breaking General news story  »

6-Month Bill Announcement…

10:45
05/23/19
05/23
10:45
05/23/19
10:45
General news
Kansas City Fed Manufacturing Index Level to be reported at 11:00 »

May Kansas City Fed…

10:45
05/23/19
05/23
10:45
05/23/19
10:45
General news
Breaking General news story  »

3-Month Bill Announcement…

RTLR

Rattler Midstream

$0.00

(0.00%)

10:43
05/23/19
05/23
10:43
05/23/19
10:43
Syndicate
Breaking Syndicate news story on Rattler Midstream »

Rattler Midstream…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

XLE

Energy Select Sector SPDR

$61.29

-2.23 (-3.51%)

10:40
05/23/19
05/23
10:40
05/23/19
10:40
Options
Massive ratio put spread in Energy SPDR ETF adjust profitable position »

Massive ratio put spread…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ACAD

Acadia

$24.78

-0.33 (-1.31%)

, ALKS

Alkermes

$24.44

-0.61 (-2.44%)

10:39
05/23/19
05/23
10:39
05/23/19
10:39
Conference/Events
JPMorgan biotech analysts to hold an analyst/industry conference call »

Biotech Analysts Fye,…

ACAD

Acadia

$24.78

-0.33 (-1.31%)

ALKS

Alkermes

$24.44

-0.61 (-2.44%)

ITCI

Intra-Cellular

$13.49

0.41 (3.13%)

NBIX

Neurocrine

$78.73

-1.14 (-1.43%)

SAGE

Sage Therapeutics

$173.51

-1.49 (-0.85%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

  • 05

    Jun

  • 27

    Sep

IDYA

IDEAYA Biosciences

$0.00

(0.00%)

10:37
05/23/19
05/23
10:37
05/23/19
10:37
Syndicate
IDEAYA Biosciences indicated to open at $14, IPO priced at $10 »

IDEAYA Biosciences (IDYA)…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

CZR

Caesars

$8.96

-0.155 (-1.70%)

10:35
05/23/19
05/23
10:35
05/23/19
10:35
Options
Caesars put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

10:30
05/23/19
05/23
10:30
05/23/19
10:30
General news
EIA natural gas storage change for week ending May 17 »

Gas inventories 100 Bcf…

RTLR

Rattler Midstream

$0.00

(0.00%)

10:25
05/23/19
05/23
10:25
05/23/19
10:25
Syndicate
Breaking Syndicate news story on Rattler Midstream »

Rattler Midstream…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

10:25
05/23/19
05/23
10:25
05/23/19
10:25
Conference/Events
JPMorgan TMT analyst to hold an Analyst/Industry conference call »

TMT Sector Specialist…

AGR

Avangrid

$50.37

-0.04 (-0.08%)

10:23
05/23/19
05/23
10:23
05/23/19
10:23
Hot Stocks
Avangrid Renewables announces new wind contract with Dairyland »

Dairyland Power…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Jun

AMX

America Movil, also tag AMOV

$14.15

-0.19 (-1.33%)

10:20
05/23/19
05/23
10:20
05/23/19
10:20
Options
Call buyer opens a notable new position in American Movil »

Call buyer opens a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RTLR

Rattler Midstream

$0.00

(0.00%)

, FANG

Diamondback Energy

$103.16

-5.71 (-5.24%)

10:19
05/23/19
05/23
10:19
05/23/19
10:19
Syndicate
Breaking Syndicate news story on Rattler Midstream, Diamondback Energy »

Rattler Midstream…

RTLR

Rattler Midstream

$0.00

(0.00%)

FANG

Diamondback Energy

$103.16

-5.71 (-5.24%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Jun

  • 23

    May

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

10:17
05/23/19
05/23
10:17
05/23/19
10:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

10:16
05/23/19
05/23
10:16
05/23/19
10:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SUNW

Sunworks

$0.68

0.0226 (3.42%)

10:15
05/23/19
05/23
10:15
05/23/19
10:15
Hot Stocks
Sunworks wins contract to build 1 MW solar project for California school »

Sunworks announced it has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RTLR

Rattler Midstream

$0.00

(0.00%)

, FANG

Diamondback Energy

$102.97

-5.9 (-5.42%)

10:15
05/23/19
05/23
10:15
05/23/19
10:15
Syndicate
Rattler Midstream indicated to open at $17.50, IPO priced at $17.50 »

Rattler Midstream (RTLR),…

RTLR

Rattler Midstream

$0.00

(0.00%)

FANG

Diamondback Energy

$102.97

-5.9 (-5.42%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Jun

  • 23

    May

TSLA

Tesla

$197.24

5.85 (3.06%)

10:15
05/23/19
05/23
10:15
05/23/19
10:15
Periodicals
Musk says Tesla produced 900 Model 3s per day this week, Reuters reports »

Tesla has produced 900…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Jun

SBUX

Starbucks

$76.11

-1.12 (-1.45%)

10:15
05/23/19
05/23
10:15
05/23/19
10:15
Options
Starbucks put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Jun

  • 25

    Jun

  • 09

    Jul

10:15
05/23/19
05/23
10:15
05/23/19
10:15
General news
FX Action: The dollar »

FX Action: The dollar…

10:15
05/23/19
05/23
10:15
05/23/19
10:15
General news
Breaking General news story  »

Week of 5/17 EIA Natural…

CMG

Chipotle

$665.03

-41.02 (-5.81%)

, BLMN

Bloomin' Brands

$18.74

-1.46 (-7.23%)

10:12
05/23/19
05/23
10:12
05/23/19
10:12
On The Fly
Chipotle seen among restaurants most at risk from African swine fever pressure »

Shares of Chipotle…

CMG

Chipotle

$665.03

-41.02 (-5.81%)

BLMN

Bloomin' Brands

$18.74

-1.46 (-7.23%)

TXRH

Texas Roadhouse

$52.05

-2.96 (-5.38%)

HRL

Hormel Foods

$38.38

-1.1 (-2.79%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

  • 23

    May

  • 28

    May

  • 29

    May

  • 29

    May

  • 13

    Jun

  • 25

    Jun

  • 27

    Jun

  • 09

    Jul

  • 27

    Aug

  • 28

    Aug

  • 13

    Nov

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.